Survival after cessation of immunotherapies in melanoma: A systematic review and meta-analysis.

ABSTRACT:

Background

Immune-checkpoint inhibitor (ICI) therapy elicits durable responses in a subset of patients with advanced melanoma. However, the appropriate timing for treatment cessation remains an unresolved issue. Moreover, some patients are required to discontinue therapy due to the occurrence of severe adverse events. Upon treatment cessation, a subset of patients maintains a durable response, while some patients relapse and require rechallenge with ICI. Criteria for a safe stop of ICI have not been established.

Objectives

The aim of this systematic review and meta-analysis was to evaluate the durability of response in melanoma patients who discontinued ICI therapy. Furthermore, the outcome of patients who electively stopped therapy was compared to that of patients who disco

SUBMITTER: Mayer KE 

PROVIDER: S-EPMC12553132 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature